Abstract
The gametocidal activities of chloroquine and artesunate were compared. The relative risk (RR) of having detectable gametocytes appear after treatment initiation was lower in artesunate-treated patients (n = 792) than in chloroquine-treated patients (n = 695) (RR = 0.29; 95% CI = 0.2 to 0.40; P < 0.0001). The duration and magnitude of gametocyte carriage were also lower for artesunate than chloroquine. By reducing the transmission of Plasmodium vivax to the vector, artesunate could therefore reduce the incidence of P. vivax malaria.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Animals
-
Antimalarials / therapeutic use*
-
Artemisinins / therapeutic use*
-
Artesunate
-
Carrier State / drug therapy
-
Carrier State / parasitology
-
Child
-
Child, Preschool
-
Chloroquine / therapeutic use*
-
Female
-
Humans
-
Malaria, Vivax / drug therapy*
-
Malaria, Vivax / parasitology*
-
Male
-
Middle Aged
-
Plasmodium vivax / drug effects*
-
Plasmodium vivax / growth & development
-
Risk Assessment
-
Sesquiterpenes / therapeutic use*
Substances
-
Antimalarials
-
Artemisinins
-
Sesquiterpenes
-
Artesunate
-
Chloroquine